Both TRXC and MNKD offer potentially big rewards, but at what cost?
Rick Wise: High surgeon intrigue in TRXC’s Senhance; Mark Massaro: EXAS could hit 2.7M in tests by 2021.
A glimpse into two of the market’s most volatile stocks right now.
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
Did this $4 billion fund make the right call on these two soaring biotechs?
Rick Wise: A lot of work left for TRXC- but end of the road holds a massive prospective audience.
Sean Lavin: TRXC investor focus to turn to U.S.
Transenterix Inc (NYSEAMERICAN:TRXC) investors are overwhelmingly excited today after the medical device maker announced the Company has received FDA 510(k) clearance for the …
Tuesday turned out to be a nightmare for shareholders of drug maker Sarepta Therapeutics Inc (NASDAQ:SRPT) and surgical robot maker Transenterix Inc (NYSEMKT:TRXC), as the stock …
